Newsletter Subject

Loneliness Needs to Be Treated Like Any Other Health Condition, Researcher Suggests

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Thu, Sep 21, 2023 10:52 PM

Email Preheader Text

Daily Headlines Thursday, September 21, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTL

[MEDPAGE TODAY]( Daily Headlines Thursday, September 21, 2023 Today's Top Stories for {NAME} [MEETING COVERAGE]( [Loneliness Needs to Be Treated Like Any Other Health Condition, Researcher Suggests]( [SPECIAL REPORTS]( ['Con Man' Gets Another Top Hospital Job, This Time at Penn Medicine]( [ONCOLOGY/HEMATOLOGY]( [TikTok Dinged for Misinformation; BRCA Risk Overestimated; Cheers for Oncology]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Evidence-Based Management of Adverse Effects of Immunotherapy in Relapsed/Refractory Multiple Myeloma]( [PUBLIC HEALTH & POLICY]( [Flawed Rules in No Surprises Act Hurt Doctors and Patients, Experts Say]( [PUBLIC HEALTH & POLICY]( [IG Live September 25: When the Healers Need Healing]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [SPECIAL REPORTS]( [Are Paxlovid and Lagevrio Equals?]( CME SPOTLIGHT [Current Evidence and Guidelines for Treatment Selection for Relapsed/Refractory Multiple Myeloma]( [ONCOLOGY/HEMATOLOGY]( [Ultrasound May Help Early Breast Cancer Patients Avoid SLNB]( [SPECIAL REPORTS]( [Medicare Advantage Ads Should Look Different This Year]( [POP MEDICINE]( ['Give This Man All the Money' for Health Messaging; We Are Human; Shocking Splinter]( CME SPOTLIGHT [Clinical Evidence for Current and Emerging Therapies in Relapsed/Refractory Multiple Myeloma]( [PRIMARY CARE]( [Gabapentin No Help for Lingering COVID-Induced Olfactory Dysfunction]( [OPINION]( [There's More to the Story of Pilots Avoiding Mental Health Care]( [OPHTHALMOLOGY]( [Smartphone App May Be a Simple Tool to Measure Abnormal Eyeball Protrusion]( CME SPOTLIGHT [Novel Mechanisms and Therapeutic Targets in Relapsed/Refractory Multiple Myeloma]( [ONCOLOGY/HEMATOLOGY]( [Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancer]( [AAD READING ROOM]( [After Latest Findings, FDA Approval for Lebrikizumab Could Happen This Fall]( [PUBLIC HEALTH & POLICY]( [The Cost of Corporatized Medicine]( CME SPOTLIGHT [Patient Perspectives in Myelofibrosis Care]( [ASCO READING ROOM]( [Catherine Marshall, MD, on Actionable Mutations in Prostate Cancer]( [SPECIAL REPORTS]( [PA's Murder Trial; Doc's Manslaughter Charge; Cardiologist's Kickback Settlement]( CME SPOTLIGHT [Advancing the Integration of CAR T-Cell Therapy in Community Oncology Centers: A Transformative Quality Improvement Initiative at a Large Community-Based Network]( # Weekly Survey [Getting Your COVID Shot?]( The CDC [recommended]( updated monovalent COVID shots for everyone age 6 months and up[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-09-21&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.